Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Uterine Cervical Dysplasia 2Squamous Intraepithelial Lesions 2Skin Neoplasms 1Sarcoma, Kaposi 1Lymphoproliferative Disorders 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

dacetuzumab 6blinatumomab 6Rituximab 4Epoetin Alfa 4Lenalidomide 3Dexamethasone 3Darbepoetin alfa 3Cyclophosphamide 3Bortezomib 3Therapeutics 2Everolimus 2Early Intervention, Educational 2Alemtuzumab 2venetoclax 1vandetanib 1tirbanibulin 1tetulomab tetraxetan lu-177 1ponatinib 1plerixafor 1pembrolizumab 1pegaspargase 1isatuximab 1imetelstat 1ibrutinib 1fludarabine 1ficlatuzumab 1ferrous sulfate 1ferric gluconate 1ferric carboxymaltose 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoproliferative Disorders × 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone × Clear all
NCT00002153 2005-06-24

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
25 enrolled
DermatologicLymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoproliferative Disorders, Sarcoma, Kaposi, Skin Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡